Investors seeking Impact and healthy returns… join us!
We recently closed the first investment round of €1.6 million in March 2023 with a small but highly motivated group of professional and private investors. The funds will be used to prepare and apply for our first clinical trial approval, planning to start by early 2025.
By end of 2024 we aim to raise a Series A of €8 million. With these proceeds we start CT Phase 1/2 pancreatic cancer studies, specifically aiming at border-line resectable PDAC. In parallel we (co-)develop other tumor applications based on the same products.
The planned investment period is 6 years, and we aim to exit as of year 6/7.
Interested to get in touch with us? Please use the contact form in contact-us page
In total we foresee two investment rounds to accelerate value and impact:
Series A of €8 Million. This can bring us up to three different Phase I/II trials in patients both in EU and USA. The Scale-up of the products is ready to early commercial scale. We will have identified multiple opportunities for out-licensing the developed products to specialized Oncology marketeers.
Series B of €20-30 Million. With this round we will be able to finalize registration of up to 3 products ready for market launch and licensing to specialized Oncology marketeers. In addition a product pipeline will be (co-)developed with a selection of off-patent and novel drugs. With this investment round we secure the optimum value for an Exit.
Pioneers and other chemo delivery companies with documented exits show valuations between 100 Million to 1 Billion US$ based on older concepts.
We have clear USP’s over these for marketeers, doctors and patients.
Impact Investment. We also make sure that our products will become available for Low Income Countries in what we call our Triple A – products: Affordable and accessible for all . We do this through collaborations with relevant NGO’s operating in LMICs and targeting Oncology.